Cantor WJ, Leblanc K, Garvey B, Watson KR, Rasymas A, Strauss BH. Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin.
Catheter Cardiovasc Interv 1999;
46:352-5. [PMID:
10348139 DOI:
10.1002/(sici)1522-726x(199903)46:3<352::aid-ccd21>3.0.co;2-7]
[Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Orgaran, a heparinoid, has been used successfully in patients with heparin-induced thrombocytopenia. We report three cases in which Orgaran was combined with the glycoprotein IIbIIa receptor antagonist Reopro during coronary angioplasty. Orgaran was given as a single intravenous bolus of 1500 anti-factor Xa units. No ischemic or hemorrhagic complications occurred during or following the procedure.
Collapse